Meta-analytic data has revealed no differences in IL-6 levels between stable, medicated patients with schizophrenia and controls, although compared with controls, IL-6 levels were similarly elevated in patients with FEP and those with acute relapse.7 A separate meta-analysis found evidence of elevated blood cytokine levels in acutely and chronically ill patients with schizophrenia.6 Focusing on particular inflammation-related symptoms, such as anhedonia, and/or illness stage may increase the chance of success for immunotherapy trials. The gene discussed is IL6; the disease is schizophrenia.